Idiopathic Pulmonary Fibrosis Is a Life-Threatening Lung Disease
AMARILLO, Texas, Nov. 7 /PRNewswire/ -- Amarillo Biosciences, Inc.
(OTC Bulletin Board: AMAR) announces that its orally-administered interferon
alpha will be tested as a treatment for idiopathic pulmonary fibrosis (IPF)
under an Advanced Technology Program Grant awarded by the State of Texas to
the Texas Tech University Health Sciences Center in Lubbock. The
$100,000 grant will be used by the Health Sciences Center to support a pilot
study of 20 patients with IPF. Amarillo Biosciences will collaborate on this
research with Lorenz O. Lutherer, MD, PhD, Professor, physiology, and Cynthia
A. Jumper, MD, Associate Professor patient care, internal medicine, and will
provide in-kind support in the form of study drug, data management and
biostatistical analysis.
IPF is an interstitial lung disease of unknown cause that affects
3-6 people per 100,000 population in the United States. IPF is characterized
by a proliferation of fibroblasts and an accumulation of interstitial
collagen, which leads to a rapid destruction of the lung. Death usually
occurs within 5 years of the initial diagnosis and there are currently no
effective treatments for IPF.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc.
said, "This is a very significant step for the Company, for our proprietary
orally-administered interferon alpha and for the thousands of people who
suffer from IPF. We are excited to partner with Texas Tech University in
developing a treatment for this growing and fatal disease."
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a pioneer in the research of low dose
orally-administered interferon alpha as a treatment for a variety of
conditions including Sjogren's syndrome, fibromyalgia syndrome, Behcet's
disease, hepatitis B and C, and opportunistic infections in patients who are
HIV positive. The Company has worked to build an extensive worldwide patent
portfolio and currently owns or licenses 20 patents relating to interferon
alpha. Additional information is available on the Amarillo Biosciences, Inc.
web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the Company's other product
candidates and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the Company's Form 10-KSB for the year ended
December 31, 2000.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html
CONTACT:
Dr. Joseph M. Cummins, President & CEO of
Amarillo Biosciences, Inc., +1-806-376-1741, ext. 13; or Jim
Drewitz, Investor Relations, +1-972-355-6070, for Amarillo
Biosciences, Inc.
|
